[Seite 119↓]

Literaturverzeichnis

1. Adil G, Murat D, Ayhan O, Ozgur TM, Ibrahim Y, Fuat PA, Rifki F. Renal cell carcinoma metastasis to the parotid gland. BJU Int 1999; 83: 861-862.

2. Allan MJ, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, Bate S, Moore J, Ahern R, Gore ME. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 2000; 83: 980-985.

3. Altmeyer A, Maki RG, Feldtweg AM, Heike M, Protopopov V, Masur SK, Srivastava PK. Tumor-specific cell surface expression of the –kdel containing, endoplasmatic reticular heat shock protein gp96. Int J Cancer 1996; 69: 340-349.

4. Amato RJ, Murray L, Wood L, Savary C, Tomasovic S, Reitsma D. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein-peptide complex-96 (HSPP-96) vaccine. Proc ASCO 1999; 18: 332a.

5. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27: 177-186.

6. Amato RJ, Wood LS, Savary C, Wood C, Hawkins EA, Reitsma DG, Srivastava P. Patients with renal cell carcinoma (RCC) using autologous tumor-derived heat shock protein-peptide complex (HSPPC-96) with or without interleukin-2. Proc ASCO 2000; 19: 454a.

7. Arnold-Schild D, Hanau D, Spehner D, Schmid C, Rammensee HG, de-la-Salle H, Schild H. Cutting-edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol 1999; 162: 3757-3760.

8. Assikis VJ, Daliani D, Pagliaro L, Wood C, Perez C, Logothetis C, Papandreou C, Hawkins ES, Srivastava PK. Phase II study of an autologous tumor derived heat shock protein-peptidecomplex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma. Proc ASCO 2003; 22: 1552.

9. Athanassiadou P, Petrakakou E, Sakelariou V, Zerva C, Liossi A, Michalas S, Athanassiades P. Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benignovarian tumours. Eur J Cancer Prev 1998; 7: 225-231.

10. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 1990; 335: 1509-1512.

11. Atzpodien J, Kirchner H, Korfer A, Hadam M, Schomburg A, Menzel T, Deckert M, Franzke A, Volkenandt M, Dallmann I, et al. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2. Tumour Biol 1993; 14: 354-359.

12. Atzpodien J, Kirchner H, Duensing S, Lopez Hanninen E, Franzke A, Buer J, Probst M, Anton P, Poliwoda H. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 1995; 13: 174-177.

13. Atzpodien J, Lopez-Hanninen E, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G, Niesel T, Scholz HJ, Wilhelm S, Pielmeier T, Zakrzewski G, Blum G, Beier J, Müller GW, Duensing S, Anton P, Allhof EP, Jonas U, Poliwoda H. Multi-institutional home-therapy trial of recombinant human interleukin-2 and interferon alpha-2 in patients with metastatic renal cell carcinoma. J Clin Oncol 1995; 13: 497-501.

14. Atzpodien J, Buer J, Sel S, Janssen J, Oevermann K. Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma. Urologe A 1999; 38: 474-478.


[Seite 120↓]

15. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85: 1130-1136.

16. Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 2002; 95: 1045-1050.

17. Atzpodien J, Kirchner H, Jonas U, Bergmann, L, Schott H, Heynemann H, Loening SA, Roigas J, Müller SC, Westerhausen H, Helbig H, Bodenstein H, Pomer S, Metzner B, Rebmann U, Hofstetter A, Oberneder R, Wandert T, Patzelt T, Reitz M, and DGCIN- German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. 13cis-retinoic acid, IFN-alpha2a, IL-2 and chemotherapy in advanced renal cell carcinoma: results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). In press, J Clin Oncol, 2003.

18. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14: 303-313.

19. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchiano A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002; 20: 4169-4180.

20. Bex A, Geis C, Metz K, Kasimir-Bauer S, Scheulen ME, Otte T, Rübben H. Expression of heat shock proteins 27 and 70 in renal cell cancer and normal tissue: An immuohistochemical study. Onkologie 1999; 22: 236-239.

21. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000; 1: 151-155.

22. Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem 2001; 276: 17163-17171.

23. Blachere NE, Li Z, Chandawarkar RY, Suto R, Navdeep S, Jaikaria NS, Basu S, Udono H, Srivastava PK. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997; 186: 1315-1322.

24. Blom DJ, De Waard-Siebinga I, Apte RS, Luyten GP, Niederkorn JY, Jager MJ. Effect of hyperthermia on expression of histocompatibility antigens and heat-shock protein molecules on three human ocular melanoma cell lines. Melanoma Res 1997; 7: 103-109.

25. Bloom HJ. Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer. Br J Cancer 1971; 25: 250-265.

26. Bonay M, Soler P, Riquet M, Battesti JP, Hance AJ, Tazi A. Expression of heat shock proteins in human lung and lung cancers. Am J Respir Cell Mol Biol 1994; 10: 453-461.

27. Botzler C, Issels R, Multhoff G. Heat-shock protein 72 cell-surface expression on human lung carcinoma cells in associated with an increased sensitivity to lysis mediated by adherent natural killer cells. Cancer Immunol Immunother 1996; 43: 226-230.

28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.

29. Breloer M, Fleischer B, von Bonin A. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. J Immunol 1999; 162: 3141-3147.


[Seite 121↓]

30. Breloer M, Marti T, Fleischer B, von Bonin A. Isolation of processed, H-2Kb-binding ovalbumin-derived peptides associated with the stress proteins HSP70 and GP96. Eur J Immunol 1998; 28: 1016-1021.

31. Brink U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G. L- and M2- pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch 1994; 424: 177-185.

32. Brinkmann OA, Bruns F, Prott FJ, Hertle L: Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC). Anticancer Res 1999; 19: 1583-1587.

33. Brinkmann OA, Herwig R, Hertle L. Role of natural killer cells for the treatment of metastatic renal cell carcinoma (MRCC). J Urol 2000; 4(Suppl): 111.

34. Brinkmann OA, Roigas J, Hertle L. Systemic immunotherapy of metastatic renal cell carcinoma and long-term outcome. Urologe A 2002; 41: 231-238.

35. Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R, Parmiani G. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001; 61: 222-227.

36. Chakrabarty A, Hillman GG, Maughan RL, Ali E, Pontes JE, Haas GP. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model. In Vivo 1994; 8: 25-31.

37. Ciancio G, Hawke C, Soloway M. The use of liver transplant techniques to aid in the surgical management of urological tumors. J Urol 2000; 164: 665-672.

38. Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 1992; 52: 3648-3654.

39. Coppin C, Porzsolt F, Kumpf J, Coldmann A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000; 3: 1-27(CD001425).

40. Dee SL, Eshghi M, Otto CS. Laryngeal metastasis 7 years after radical nephrectomy. Arch Pathol Lab Med 2000; 124: 1833-1834.

41. DiBiase SJ, Valicenti RK, Schultz D, Xiem Y, Gomella LG, Corn BW. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: Support for dose escalation based on a biological model. J Urol 1997; 158: 746-749.

42. DiCesare S, Poccia F, Mastino A, Colizzi V. Surface expressed heat-shock proteins by stressed or human immunodeficiency virus (HIV)-infected lymphoid cells represent the target for antibody-dependent cellular cytotoxicity. Immunology 1992; 76: 341-343.

43. Dressel R, Lubbers M, Walter L, Herr W, Gunther E. Enhanced susceptibility to cytotoxic T lymphocytes without increase of MHC class I antigen expression after conditional overexpression of heat shock protein 70 in target cells. Eur J Immunol 1999; 29: 3925-3935.

44. Durr HR, Maier M, Pfahler M, Baur A, Refior HJ. Surgical treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop 1999; 367: 283-290.

45. Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M. Phase II trail of interleukin-2, interferon-alpha, and 5-fluorouracil in metastatic renal cell cancer: A cytokine working group study. Clin Cancer Res 2000; 6: 3442-3450.

46. Dybal EJ, Haas GP, Maughan RL, Sud S, Pontes JE, Hillman GG. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. J Urol 1992; 148: 1331-1337.

47. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase (TUM2-PK) in human carcinomas, Anticancer Res 1997; 17: 3153-3156.


[Seite 122↓]

48. Elias L, Binder M, Mangalik A, Clark D, Morrison B, Altobelli KK, Smith A. Pilot trail of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon- a for advanced renal cell carcinoma. Am J Clin Oncol 1999; 22: 156-161.

49. Ferrarini M, Heltai S, Zocchi RM, Rugarli C. Unusual expression and localization in heat-shock proteins in human tumor cells. Int J Cancer 1992; 51: 613-619.

50. Ficarra V, Righetti R, D'Amico A, Rubilotta E, Novella G, Malossini G, Mobilio G. Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology 2001; 61: 10-15.

51. Figlin RA. Review article - Renal cell carcinoma: Management of advanced disease. J Urol 1999; 161: 381-386.

52. Finney R. The value of radiotherapy in the treatment of hypernephroma--a clinical trial. Br J Urol 1973; 45: 258-269.

53. Fischer G, Holzrichter S, Reinacher M, Heinrichs M, Dembowski J, Eigenbrodt E. Immunohistochemical demonstration of L- and M2-pyruvate kinase in primary renal cell carcinomas and their metastases. Verh Dtsch Ges Pathol 1989; 73: 422-443.

54. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6: 55-57.

55. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med 2001; 345: 1655-1659.

56. Flanigan R. Commentary. Urologic Oncology 2002; 7: 84.

57. Fojo AT, Shen DW, Mickley LA, Pastan I, Gottesman MM. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987; 5: 1922-1927.

58. Fossa SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol 1982; 8: 340-342.

59. Fossa SD, Lien HH, Lindegaard M. Effect of recombinant interferon alfa on bone metastases of renal-cell carcinoma. N Engl J Med 1991; 324: 633-634.

60. Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999; 162: 1730-1738.

61. Gerner EW, Schneider MJ. Induced thermal resistance in HeLa cells. Nature 1975; 256: 500-502.

62. Gershanovich MM, Moiseyenko VM, Vorobjev AV, Kapyla H, Ellmen J, Anttila M. High-dose toremifene in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 1997; 39: 547-551.

63. Giehl JP, Kluba T. Metastatic spine disease in renal cell carcinoma--indication and results of surgery. Anticancer Res 1999; 19: 1619-1623.

64. Gross C, Hansch D, Gastpar R, Multhoff G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol Chem 2003; 384: 267-279.

65. Gschwend J, Maier S, Flohr P, de Petriconi R, Hautmann RE. Venous tumor invasion by renal cell carcinoma. Surgical technique, complications and survival rate. Urologe A 1994; 33: 440-446.

66. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 992-993.

67. Hantschel M, Pfister K, Jordan A, Scholz R, Andreesen R, Schmitz G, Schmetzer H, Hiddemann W, Multhoff G. Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones 2000; 5: 438-442.


[Seite 123↓]

68. Heffess CS, Wenig BM, Thompson LD. Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases. Cancer 2002; 95: 1869-1878.

69. Heike M, Hertkorn C, Reitsma DJ, Kommoss F, Simiantonaki N, Woelfel T, Dippold WG, Junginger T, Srivastava PK, Galle PR. Pilot trail of vaccination with autologous tumor-derived gp96 heat shock protein-peptide complex (HSPPC-96) in patients after surgery for gastric carcinoma. Proc ASCO 2000; 19: 466a.

70. Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics 2001; 57: 114-119.

71. Henle KJ, Leeper DB. Interaction of hyperthermia and radiation in CHO cells: recovery kinetics. Radiat Res 1976; 66: 505-518.

72. Henle KJ, Dethlefsen LA. Heat fractionation and thermotolerance: a review. Cancer Res 1978; 38: 1843-1851.

73. Henson DE, Fielding LP, Grignon DJ, Page DL, Hammond ME, Nash G, Pettigrew NM, Gorstein F, Hutter RV. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Arch Pathol Lab Med 1995; 119: 1109-1112.

74. Hettinga JV, Lemstra W, Konings AW, Kampinga HH. Cisplatin sensitivity and thermochemosensitisation in thermotolerant cDDP-sensitive and -resistant cell lines. Br J Cancer 1995; 71: 498-504.

75. Heufelder AE, Wenzel BE, Bahn RS. Cell surface localization of a 72 kilodalton heat shock protein in retro-ocular fibroblasts from patients with Grave`s ophthalmopathy. J Clin Endocrinol Metab 1992; 74: 732-736.

76. Hightower LE, Guidon PT Jr. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J Cell Physiol 1989; 138: 257-266.

77. Hirai I, Sato N, Qi W, Ohtani S, Torigoe T, Kikuchi K. Localization of pNT22 70 kDa heat shock cognate-like protein in the plasma membrane. Cell Struct Funct 1998; 23: 153-158.

78. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 2002; 167: 57-60.

79. Hoffman AD, Engelstein D, Bogenrieder T, Papandreou CN, Steckelman E, Dave A, Motzer RJ, Dmitrovsky E, Albino AP, Nanus DM. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 1996; 2: 1077-1082.

80. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HGW. Chemoimmunotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 1996; 156: 18-21.

81. Hugo F, Fischer G, Eigenbrodt E: Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Res 1999; 19: 2753-2757.

82. Huland E, Heinzer H, Timm S, Alamian M, Huland H. Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status. Urologe A 2002; 41: 282-287.

83. Huot J, Roy G, Lambert H, Chretien P, Landry J. Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein. Cancer Res 1991; 51: 5245-5252.

84. Ishii T, Udono H, Yamano T, Ohta H, Uenaka A, Ono T, Hizuta A, Tanaka N, Srivastava PK, Nakayama E. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 1999; 162: 1303-1309.


[Seite 124↓]

85. Ito A, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 2001; 50: 515-522.

86. Jacobsen KD, Folleras G, Fossa SD. Metastases from renal cell carcinoma to the humerus or the shoulder girdle. Br J Urol 1994; 73: 124-128.

87. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000; 88: 232-238.

88. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998; 51: 203-205.

89. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.

90. Jung MY, Huryk RF, Yoshimura I, Fair WR, Gregor PD. Protective immunity to Dunning G tumor in rats immunized with heat shock protein gp96 purified from G tumor. Proc Annu Meet Am Assoc Cancer Res 1996; 37: A3165.

91. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am statist Assoc 1958; 53: 457-481.

92. Kaplan S, Ekici S, Dogan R, Demircin M, Ozen H, Pasaoglu I. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Am J Surg 2002; 183: 292-299.

93. Kaufmann SH. Heat shock proteins and the immune response. Immunol Today 1990; 11: 129-136.

94. Kaur J, Srivastava A, Ralhan R. Expression of 70-kDa heat shock protein in oral lesions: marker of biological stress or pathogenicity. Oral Oncol 1998; 34: 496-501.

95. Kaur J, Das SN, Srivastava A, Ralhan R. Cell surface expression of 70 kDa heat shock protein in human oral dysplasia and squamous cell carcinoma: correlation with clinicopathological features. Oral Oncol 1998; 34: 93-98.

96. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987; 13: 665-672.

97. Klapdor R, Bahlo M, Fenner C. Tumormarker M2-PK in the follow up of pancreatic and colorectal cancer disease. Abstract, 10th International Hamburg Symposium on Tumor markers, Hamburg, Deutschland, 05.-07.12.1999.

98. Kohler G, Veelken H, Rosenthal F, Mackensen A, Lindemann A, Schaefer HE, Lahn M. Oncogene and HSP-70 expression in primary tumor cell cultures of renal cell carcinoma compared to their corresponding cell line. Anticancer Res 1997; 17: 3225-3231.

99. Koshiyama M, Konishi I, Mandai M, Komatsu T, Yamamoto S, Nanbu K, Mori T. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status. Virchows Arch 1995; 425: 603-609.

100. Kubista B, Trieb K, Blahovec H, Kotz R, Micksche M. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis. Anticancer Res 2002; 22: 789-792.

101. Kuczyk MA, Bokemeyer C, Kohn G, Stief CG, Machtens S, Truss M, Hofner K, Jonas U. Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer. Br J Urol 1997; 80: 18-24.

102. Kuczyk M, Munch T, Machtens S, Wunning T, Grunewald V, Stief CG, Hofner K, Jonas U. Therapy for kidney cell carcinoma with cava thrombus. Importance of extracorporeal circulation and prognostic value of cranial tumor extension. Urologe A 1999; 38: 460-465.


[Seite 125↓]

103. Lammert E, Arnold D, Nijenhuis M, Momburg F, Hämmerling GJ, Brunner J, Stevanovic S, Rammensee HG, Schild H. The endoplasmatic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur J Immunol 1997; 27: 923-927.

104. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159: 1163-1167.

105. Lewis JJ, Janetzki S, Livingston PO, Desantis D, Williams L, Klimstra D, Reistma D, Houghton AN, Srivastava P. Pilot trail of vaccination with autologous tumor derived gp96 heat shock protein-peptide complex (HSPPC-96) in patients with resected pancreatic adenocarcinoma. Proc ASCO 1999; 18: 1687a.

106. Li GC, Mivechi NF, Weitzel G. Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Int J Hyperthermia 1995; 11: 459-488.

107. Lichtenfels R, Kellner R, Bukur J, Beck J, Brenner W, Ackermann A, Seliger B. Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2002; 2: 561-570.

108. Lopez Hanninen E, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155: 19-25.

109. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer, Anticancer Res 2000; 20: 5077-5082.

110. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.

111. Matzinger P. An innate sense of danger. Semin Immunol 1998; 10: 399-415.

112. Mazurek S, Scheefers-Borchel U, Scheefers H, Michel A, Basenau D, Fischer G, Dahlmann N, Laumen R, Eigenbrodt E. Die Bedeutung der Pyruvatkinase in der Onkologie. Notabene Medici 1993; 3: 97-103.

113. Mazzaferro V, Coppa JC, Carrabba M, Rivoltini L, Schiavo M, Marchiano A, Romito R, Pulvirenti A, Camerini T, Regalia E, Gianessi W, Camerini R, Lewis JJ, Srivastava PK, Parmiani G. Vaccination with autologous tumor derived heat shock protein peptide complex gp-96 (HSPPC-96) following curative resection of colorectal liver metastases. Proc ASCO 2001; 20: 256a.

114. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-17.

115. Metzner B, Siegmund R, Kirchner H, Atzpodien J, Illiger HJ. Sprechen Knochenmetastasen auf eine Immuntherapie mit Interleukin-2 und Interferon-alpha-2b beim Nierenzellkarzinom an? Tumordiagn u Ther 1991; 12: 192-6.

116. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H. Guidelines on renal cell cancer. Eur Urol 2001; 40: 252-255.

117. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-970.

118. Molto L, Carballido J, Manzano L, Martinez-Martin B, Esquivel F, Chafer J, Olivier C, Alvarez-Mon M. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2. J Immunother 1999; 22: 260-267.

119. Moseley PL. Heat shock proteins and heat adaptation of the whole organism. J Appl Physiol 1997; 83: 1413-1417.


[Seite 126↓]

120. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995; 13: 1950-1957.

121. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-875.

122. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.

123. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-2980.

124. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417.

125. Multhoff G, Botzler K, Wiesnet M, Müller E, Meier T, Wilmanns W, Issels RD. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 1995; 61: 272-279.

126. Multhoff G, Botzler K, Wiesnet M, Eißner G, Issels RD. CD3 large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood 1995; 86: 1374-1382.

127. Multhoff G, Hightower LE. Cell surface expression of heat shock proteins and the immune response. Cell Stress Chaperones 1996; 1: 167-176.

128. Multhoff G. Heat shock protein 72 (HSP72), a hyperthermia-inducible immunogenic determinant on leukemic K562 and Ewing's sarcoma cells. Int J Hyperthermia 1997; 13: 39-48.

129. Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels R. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol 1997; 158: 4341-4350.

130. Multhoff G, Botzler C, Issels R. The role of heat shock proteins in the stimulation of an immune response. Biol Chem 1998; 379: 295-300.

131. Multhoff G, Mizzen L, Winchester CC, Milner CM, Wenk S, Eissner G, Kampinga HH, Laumbacher B, Johnson J. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp Hematol 1999; 27: 1627-1636.

132. Multhoff G, Pfister K, Gehrmann M, Hantschel M, Gross C, Hafner M, Hiddemann W. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones 2001; 6: 337-344.

133. Multhoff G. Activation of natural killer cells by heat shock protein 70. Int J Hyperthermia 2002; 18: 576-585.

134. Musch MW, Kaplan B, Chang EB. Role of increased basal expression of heat shock protein 72 in colonic epithelial c2BBE adenocarcinoma cells. Cell Growth Differ 2001; 12: 419-426.

135. Naitoh J, Kaplan A, Dorey F, Figlin R, Belldegrun A. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: Long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol 1999; 162: 46-50.

136. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-1278.


[Seite 127↓]

137. Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P, Gomez F. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 2000; 18: 4009-4015.

138. Nishisaka N, Jones RF, Morse P, Kuratsukuri K, Romanowski R, Wang CY, Haas GP. Inhibition of lung metastases of murine renal cell carcinoma by the combination of radiation and interferon-alpha-producing tumor cell vaccine. Cytokines Cell Mol Ther 2000; 6: 199-206.

139. Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJ, Kuppner MC, Roos M, Kremmer E, Asea A, Calderwood SK, Issels RD. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002; 169: 5424-5432.

140. Oesterreich S, Schunck H, Benndorf R, Bielka H. Cisplatin induces the small heat shock protein hsp25 and thermotolerance in Ehrlich ascites tumor cells. Biochem Biophys Res Commun 1991; 180: 243-248.

141. Oremek GM, Eigenbrodt E, Rädle J, Zeuzem ST, Seiffert U. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res 1997; 17: 3031-3034.

142. Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel K-H. The pyruvate kinase isoenzyme tumor M2 (TUM2-PK) as a tumor marker for renal cell carcinoma, Anticancer Res 1999; 19: 2599-2601.

143. Palleros DR, Shi L, Reid KL, Fink AL. HSP70-Protein Complexes: Complex stability and conformation of bound substrate protein. J Biol Chem 1994; 269: 13107-13114.

144. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611-1623.

145. Pavone L, Andrulli S, Santi R, Majori M, Buzio C. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer. Cancer Immunol Immunother 2001; 50: 82-86.

146. Peng P, Ménoret A, Srivastava PK. Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. J Immunol Meth 1997; 204: 13-21.

147. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814-825.

148. Plawner J. Results of surgical treatment of kidney cancer with solitary metastasis to contralateral adrenal. Urology 1991; 37: 233-236.

149. Protti MP, Heltai S, Bellone M, Ferrarini M, Manfredi AA, Rugarli C. Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. Cancer Lett 1994; 85: 211-216.

150. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-2867.

151. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994; 12: 206-212.

152. Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C, Douillard J-Y, Caty A, Geoffrois L, Ferrero J-M, Linassier C, Drevon M, Negrier S. Subcutaneous interleukin-2, interferon alpha-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trail. J Clin Oncol 1998; 16: 2728-2732.


[Seite 128↓]

153. Riccobon A, Ridolfi R, DePaola F, Barzanti F, Mosconi G, Ortolano F, Stefanelli M, Ibrahim T, Ridolfi L, Fabbri M, Flamini E, Amadori D. Vaccination with dendiritc cells (DC) pulsed with heat shock proteins (HSP) or lysate from autologous tumor in advanced melanoma patients. Proc ASCO 2000; 19: 469a.

154. Ridout MS, Demetrio CG, Firth D. Estimating intraclass correlation for binary data. Biometrics 1999; 55: 137-48.

155. Robson C, Churchill B, Anderson W. The results of radical nephrectomy for RCC’s. J Urol 1969: 101; 297-301.

156. Roigas J, Wallen ES, Moseley PL. Cell surface expression of HSP72 enhances NK lysis in the human renal carcinoma cell line ACHN. Adv Exp Med Biol 1998; 451: 195-200.

157. Roigas J, Wallen ES, Loening SA, Moseley PL. Effects of combined treatment of chemotherapeutics and hyperthermia on survival and the regulation of heat shock proteins in Dunning R3327 prostate carcinoma cells. Prostate 1998; 34: 195-202.

158. Roigas J, Wallen ES, Loening SA, Moseley PL. The role of heat shock proteins for vaccination models in renal cell carcinoma. J Urol 1999; 161(Suppl): 145.

159. Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA. Tumor M2-Pyruvate Kinase (TUM2-PK) in Plasma of Patients with Urological Tumors. Tum Biol 2001; 22: 282-285.

160. Roigas J, Schroeder J, Rudolph B, Schnorr D. Renal cell cancer with a symptomatic heart metastasis. BJU Int 2002; 90: 622-623.

161. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-1492.

162. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897.

163. Ruckert RI, Schnorr D, Turk H, Muller JM. Surgical therapy of tumor embolism of the vena cava in renal cell carcinoma. Langenbecks Arch Chir Suppl Kongressbd 1998; 115: 240-245.

164. Samland D, Steinbach F, Reiher F, Schmidt U, Gruss A, Allhoff EP. Results of chemoimmunotherapy with interleukin-2, interferon-a2 and 5-fluorouracil in the treatment of metastatic renal cell cancer. Eur Urol 1999; 35: 204-209.

165. Santarosa M, Favaro D, Quaia M, Galligioni E. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer 1997 ; 33 : 873-877.

166. Schneekloth C, Korfer A, Hadam M, Lopez Hanninen E, Menzel T, Schomburg A, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo. Acta Haematol 1993; 89: 13-21.

167. Schnorr D, Rückert RI, Bohm J, Roigas J, Türk I, Kastein A. Radikaloperationen von Nierentumoren mit intrakavalen und intrakardialen Tumorthromben. In Nierenzellkarzinom – Renal Cell Carcinoma.Eds. D. Schnorr, S.A. Loening. Blackwell Wissenschafts-Verlag Berlin, Wien, 1998, pp. 99-110.

168. Schomburg A, Kirchner H, Fenner M, Menzel T, Poliwoda H, Atzpodien J. Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. Eur J Cancer 1993; 29A: 737-740.

169. Schroder A, Lampel A, Eggersmann C, Thuroff JW. Controversies in surgical therapy of renal cell carcinoma. Urologe A 1997; 36: 460-466.


[Seite 129↓]

170. Siebels M, Oberneder R, Buchner A, Zaak D, Mack A, Petrides PE, Hofstetter A, Wowra B. Ambulatory radiosurgery in cerebral metastatic renal cell carcinoma. 5-year outcome in 58 patients. Urologe A 2002; 41: 482-488.

171. Sierra-Rivera E, Voorhees GJ, Freeman ML. Gamma irradiation increases hsp-70 in Chinese hamster ovary cells. Radiat Res 1993; 135: 40-45.

172. Smith EM, Kursh ED, Makley J, Resnick MI. Treatment of osseous metastases secondary to renal cell carcinoma. J Urol 1992; 148: 784-787.

173. Sobin LH, Wittekind C. TNM classification of malignant tumors, 6th edition. Wiley-Liss, New York 2002, pp. 193-195.

174. Srigley JR, Hutter RV, Gelb AB, Henson DE, Kenney G, King BF, Raziuddin S, Pisansky TM. Current prognostic factors – renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 994-996.

175. Srivastava PK, DeLeo A, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 1986; 83: 3407-3411.

176. Srivastava PK. Peptide-binding heat shock proteins in the endoplasmatic reticulum: Role in immune response to cancer and in antigen presentation. Adv Cancer Res 1993; 62: 153-178.

177. Srivastava PK. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods 1997; 12: 165-171.

178. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998; 16: 1820-1825.

179. Staehler G, Liedl B, Kreuzer E, Sturm W, Schmiedt E. Kidney cancer with invasion of the vena cava: classification, surgical strategy and results of treatment. Urologe A 1987; 26: 46-50.

180. Staehler G, Brkovic D. Renal cell carcinoma with vena cava involvement. Surgical strategies and results. Urologe A 1997; 36: 109-116.

181. Staehler G, Brkovic D. The role of radical surgery for renal cell carcinoma with extension into the vena cava. J Urol 2000; 163: 1671-1675.

182. Stahl M, Wilke H, Schmoll HJ, Schober C, Diedrich H, Casper J, Freund M, Poliwoda H. A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol 1992; 3: 167-168.

183. Steinberg P, Storkel S, Oesch F, Thoenes W. Carbohydrate metabolism in human renal clear cell carcinomas. Lab Invest 1992; 67: 506-511.

184. Stephens ND, Barton SL, Smith AY, Paul RW, Neidhardt JA, Griffith JK. GM-CSF secretion in primary cultures of normal and cancerous human renal cells. Kidney Int 1996; 50: 1044-1050.

185. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 987-989.

186. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269: 1585-1588.

187. Swanson DA, Orovan WL, Johnson DE, Giacco G. Osseous metastases secondary to renal cell carcinoma. Urology 1981; 18: 556-561.

188. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278: 117-120.

189. Thoenes W, Störkel S. Die Pathologie der benignen und malignen Nierenzelltumoren. Urologe A 1991; 30: W41-W50.


[Seite 130↓]

190. Thomas ML, Samant UC, Deshpande RK, Chiplunkar SV. Gammadelta T cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis. Cancer Immunol Immunother 2000; 48: 653-659.

191. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppaccario A, Vile RG. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999; 163: 1398-1408.

192. Toma S, Monteghirfo S, Tasso P, Nicolo G, Spadini N, Palumbo R, Molina F. Antiproliferative and synergistic effect of interferon alpha-2a, retinoids and their association in established human cancer cell lines. Cancer Lett 1994; 82: 209-216.

193. Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu JM, Chastang C. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Proleukin Program Cooperative Group. J Clin Oncol 1998; 16: 2505-2513.

194. Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S. Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy. Hum Pathol 1998; 29: 1050-1055.

195. Trieb K, Kohlbeck R, Lang S, Klinger H, Blahovec H, Kotz R. Heat shock protein 72 expression in chondrosarcoma correlates with differentiation. J Cancer Res Clin Oncol. 2000; 126: 667-670.

196. Tsuji Y, Goto A, Hara I, Ataka K, Yamashita C, Okita Y, Kamidono S. Renal cell carcinoma with extension of tumor thrombus into the vena cava: surgical strategy and prognosis. J Vasc Surg 2001; 33: 789-796.

197. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993; 178: 1391-1396.

198. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 1994; 152: 5398-5403.

199. Udono H, Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: Tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Nat Acad Sci 1994; 91: 3077-3081.

200. Van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 2000; 82: 772-776.

201. Varga Z, Hegele A, Stief T, Heidenreich A, Hofmann R. Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker. Urol Res 2002; 30: 122-125.

202. Vendetti S, Cicconi R, Piselli P, Vismara D, Cassol M, Delpino A. Induction and membrane expression of heat shock proteins in heat-treated HPC-4 cells is correlated with increased resistance to LAK-mediated lysis. J Exp Clin Cancer Res 2000; 19: 329-334.

203. Voshol H, Dullens HF, Den Otter W, Vliegenthart JF. Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity. J Immunol Methods 1993; 165: 21-30.

204. Wallen ES, Roigas J, Moseley PL. Methods for purifying and synthesizing heat shock protein complexes. United States Patent Office, 5,747,332, May 5, 1998.


[Seite 131↓]

205. Wallen ES, Roigas J, Moseley PL. Purified heat shock protein complexes. United States Patent Office, 6,066,714, May 23, 2000.

206. Wallen ES, Roigas J, Moseley PL. Purified heat shock protein complexes. United States Patent Office, 6,433,141, August 13, 2002.

207. Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): The dimeric form of pyruvate kinase type M2 (TUM2-PK), Anticancer Res 1999; 19: 2583-2590.

208. Wechsel HW, Petri E, Feil G, Nelde H, Bichler K. Renal cell carcinoma. Immunhistological study to the expression of the inactive form of the pyruvate kinase, Urologe A 1999; 38: 583-585.

209. Wei Y, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of gamma delta T cells and heat shock protein 70. Cancer Res 1996; 56: 1104-1110.

210. Welch WJ. Mammalian stress response: Cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Review 1992; 72: 1063-1081.

211. Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M. Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 1998; 10: 609-617.

212. Wernecke KD. Persönliche Mitteilung. Berlin, 13.08.2003.

213. Winfield JB. Stress proteins, arthritis, and autoimmunity. Arthritis Rheum 1989; 32: 1497-1504.

214. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993; 20: 283-295.

215. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22: 42-60.

216. Younes A, Fayad LE, Pro B, McLaughlin P, Hagemeister FB, Mansfield P, Clayman G, Medeiros LJ, Lewis J, Srivastava PK. Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) in low-grade lymphoma. Proc ASCO 2003; 22: 2294.

217. Younes E, Haas GP, Dezso B, Ali E, Maughan RL, Kukuruga MA, Montecillo E, Pontes JE, Hillman GG. Local tumour irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol 1995; 165: 243-251.

218. Younes E, Haas GP, Dezso B, Ali E, Maughan RL, Montecillo E, Pontes JE, Hillman GG. Radiation-induced effects on murine kidney tumour cells: role in the interaction of local irradiation and immunotherapy. J Urol 1995; 153: 2029-2033.

219. Zisman A, Pantuck AJ, Chao DH, Wieder JA, Dorey F, Said JW, Kernion JB, Figlin R, Belldegrun AS. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol 2002; 168: 962-967.

220. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol 2002; 20: 1368-1374.

221. Zisman A, Chao DH, Pantuck AJ, Kim HJ, Wieder JA, Figlin RA, Said JW, Belldegrun AS. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol 2002; 168: 950-955.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
10.06.2004